REGN SEC Filings

Regeneron Pharmaceuticals, Inc. reported solid financial performance for the fiscal year ending December 31, 2025, with revenues reaching $14.34 billion and net income at $4.50 billion. The company's strategic focus on scientific innovation and integrated development, manufacturing, and commercialization capabilities continues to drive growth. Key products like Dupixent and EYLEA HD demonstrated strong performance, contributing significantly to the company's top-line results, despite increased competition and the ongoing transition from EYLEA to EYLEA HD. The company also highlighted its robust pipeline with numerous product candidates in various stages of clinical development across multiple therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron continues to invest heavily in research and development to fuel future growth. However, investors should be aware of potential headwinds. The company is heavily reliant on its flagship products, EYLEA and Dupixent, and faces significant competition, including from biosimilars for EYLEA. Regulatory and manufacturing challenges were noted, particularly concerning a third-party manufacturer (Catalent) that led to delays in FDA approvals for EYLEA HD's pre-filled syringe and Ordspono. The company is actively managing these issues by onboarding new manufacturers and addressing regulatory feedback. The evolving healthcare landscape, including pricing pressures and potential regulatory changes, also presents risks that investors should monitor.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on January 29, 2026, to announce its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release detailing these results is attached as Exhibit 99.1 and is incorporated by reference. Investors should refer to this press release for specific figures related to revenue, profitability, and operational performance. This filing is crucial for understanding the company's recent financial health and its trajectory heading into the new fiscal year. The information is being furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, meaning it does not automatically update previous SEC filings. Investors should consult the press release directly for comprehensive details.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 12, 2026, providing a corporate update and preliminary unaudited financial information for the fourth quarter and full year 2025. The update, delivered at the J.P. Morgan Healthcare Conference, highlighted two key financial items: an anticipated acquired in-process research and development (IPR&D) charge of approximately $19 million, expected to reduce Q4 2025 diluted earnings per share by roughly $0.14 on both a GAAP and non-GAAP basis. This charge reflects investments in early-stage development projects. Additionally, the company reported a $60 million charge to selling, general, and administrative expenses in Q4 2025 related to its matching program for donations to Good Days, a non-profit supporting retinal disease research. Regeneron matched the $60 million in donations received by the Fund for this initiative.

Regeneron Pharmaceuticals, Inc. reported strong financial results for the nine months ended September 30, 2025, with total revenues of $10.46 billion, a slight increase from the same period in 2024. Net income also saw a positive trend, reaching $3.66 billion, up from $3.49 billion in the prior year. Diluted earnings per share were $33.61, an increase from $30.23. The company's product sales, while experiencing a decline in EYLEA revenue due to increased competition and the transition to EYLEA HD, were bolstered by significant growth in Dupixent and Libtayo sales. Collaboration revenue, primarily from Sanofi, also showed robust growth, driven by strong Dupixent performance. Operating expenses increased due to higher R&D investments, particularly in direct R&D for key programs, though SG&A expenses decreased. The company continued its share repurchase program and declared regular quarterly dividends, underscoring a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2025. The company issued a press release on October 28, 2025, detailing these results, which is being furnished as an exhibit to this filing. Investors should refer to the press release (Exhibit 99.1) for specific financial figures and operational updates, as it contains the core information regarding the company's performance during the period. The filing itself primarily serves as a notification and mechanism to incorporate the press release into the SEC's public record. While the 8-K does not contain the detailed financial tables or management commentary directly, the attached press release is the key document for understanding Regeneron's recent performance and outlook. Investors are advised to review this press release thoroughly for a comprehensive understanding of the reported results.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing an expected acquired in-process research and development (IPR&D) charge of approximately $83 million on a pre-tax basis for the third quarter of 2025. This charge is primarily linked to an $80 million upfront payment made to Hansoh Pharmaceuticals Group Company Limited under a 2025 license agreement. The company anticipates this IPR&D charge will reduce both GAAP and non-GAAP net income per diluted share by approximately $0.68 for the quarter.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2025, to report its financial and operating results for the second quarter ended June 30, 2025. The primary purpose of this filing is to furnish the accompanying press release (Exhibit 99.1) which contains detailed financial and operational performance metrics for the period. Investors should refer to this press release for specific figures regarding revenue, profitability, and key product performance. This report serves as the official notification of the company's quarterly performance. While the 8-K itself is brief, it directs stakeholders to the press release for the substantive financial disclosures. Investors are advised to review the press release for insights into Regeneron's strategic progress, any notable product updates, and forward-looking guidance, which will be crucial for assessing the company's current valuation and future prospects.

Regeneron Pharmaceuticals, Inc. (REGN) reported its financial results for the quarter and six months ended June 30, 2025. Total revenues for the six months ended June 30, 2025, were $6.704 billion, a slight increase from $6.692 billion in the same period of 2024. Net income for the first six months of 2025 was $2.200 billion, or $20.02 per diluted share, compared to $2.154 billion, or $18.68 per diluted share, in the prior year's period. The company's balance sheet shows total assets of $38.219 billion as of June 30, 2025, and total stockholders' equity of $29.939 billion. The company saw a decrease in net product sales, primarily driven by a significant decline in EYLEA sales, which was partially offset by growth in EYLEA HD and Dupixent. Collaboration revenues, largely from the Sanofi and Bayer partnerships, showed a substantial increase, driven by higher profit shares, particularly from Dupixent. Operating expenses, notably research and development, increased year-over-year, reflecting continued investment in the company's pipeline. Investors should note the ongoing legal proceedings related to EYLEA biosimilar challenges and the company's active share repurchase program, which repurchased approximately $2.122 billion of common stock during the first six months of 2025. The company also declared and paid quarterly dividends.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K detailing the outcomes of its 2025 Annual Meeting of Shareholders held on June 13, 2025. The key takeaways for investors revolve around significant governance changes and shareholder confidence in the company's direction and leadership. Shareholders overwhelmingly re-elected all Class I directors and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2025, indicating strong support for the current board and financial oversight. Furthermore, investors approved an advisory vote on executive compensation, demonstrating confidence in the company's compensation practices. A notable governance shift occurred with the approval to declassify the board of directors, moving towards a more standard annual election of all board members. However, proposals to eliminate certain supermajority vote requirements for specific charter amendments did not pass, suggesting a desire among some shareholders for existing protections or a cautious approach to altering these provisions.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on April 28, 2025, to report its first quarter 2025 financial and operating results. The key details of these results are provided in a press release furnished as Exhibit 99.1 to the filing. Investors should refer to this press release for the specific financial performance and operational achievements during the quarter ended March 31, 2025. The filing itself primarily serves as a notification of the release of this information, rather than containing extensive new disclosures within the 8-K document itself.

Regeneron Pharmaceuticals, Inc. reported mixed results for the first quarter of 2025. Total revenues decreased slightly year-over-year to $3.03 billion from $3.15 billion, primarily driven by a significant decline in U.S. EYLEA sales due to competitive pressures and the transition to EYLEA HD. However, this was partially offset by strong growth in Dupixent and a solid performance from EYLEA HD in the U.S. Net income increased to $808.7 million, or $7.27 per diluted share, compared to $722.0 million, or $6.27 per diluted share, in the prior year's quarter. This improvement was supported by an increase in collaboration revenue, particularly from Sanofi, and a favorable shift in other income (expense), net. The company also announced its first quarterly cash dividend and continued its share repurchase program, signaling a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. reported robust financial performance for the fiscal year ended December 30, 2024, with revenues reaching $14.2 billion and net income of $4.4 billion, marking a significant increase from the prior year. The company's flagship products, EYLEA/EYLEA HD and Dupixent, continue to be key revenue drivers, with Dupixent in particular showing strong growth in collaboration revenue. Regeneron's extensive pipeline remains a focus, with numerous product candidates in various stages of clinical development across multiple therapeutic areas. The company is also actively managing its manufacturing and supply chain capabilities, investing in facility expansions and process validation to support future growth. Shareholder returns were bolstered by a new share repurchase program and the initiation of a quarterly dividend, indicating confidence in the company's financial health and future prospects.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report disclosing its financial and operating results for the fourth quarter and full year ended December 31, 2024. The report also announces significant capital allocation decisions by the company's board of directors, marking a new phase in returning value to shareholders. Investors should note the initiation of a quarterly cash dividend program and a substantial share repurchase authorization alongside the earnings release. The company declared its inaugural quarterly cash dividend of $0.88 per share, payable on March 20, 2025, to shareholders of record on February 20, 2025. This signifies a commitment to consistent shareholder returns. Furthermore, Regeneron has authorized an additional $3.0 billion for share repurchases, underscoring confidence in its financial position and the company's valuation. The full details of the financial and operating results are available in the accompanying press release (Exhibit 99.1).

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2025, to provide business updates and highlights from its clinical pipeline presented at the 43rd Annual J.P. Morgan Healthcare Conference. The filing includes preliminary, unaudited financial information for the fourth quarter and full year 2024, which is subject to finalization. Investors should note that the company anticipates an acquired in-process research and development (IPR&D) charge of approximately $14 million on a pre-tax basis for Q4 2024, primarily related to asset acquisitions. This charge is expected to reduce GAAP and non-GAAP net income per diluted share by approximately $0.11 for the quarter. The company has also incorporated by reference a press release and conference presentation, which are expected to contain further details on its pipeline and strategic updates. While this information is furnished to the SEC, it is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act unless expressly incorporated into a filing. Investors are advised to review the full details within the referenced exhibits for a comprehensive understanding of Regeneron's recent performance and future outlook.

Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2024, with total revenues reaching $10.41 billion, an increase of 7.5% compared to the same period in the prior year. Net income also saw a significant rise, up 25% to $3.49 billion. This growth was driven by strong performance across key products, notably Dupixent and EYLEA HD, which showed substantial revenue increases of 25% and approximately 4% respectively in their respective segments. The company also saw positive growth in Libtayo and Praluent. Research and development expenses increased by approximately 14% year-over-year, reflecting continued investment in the company's pipeline. The company ended the period with a strong liquidity position, with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities, while also actively repurchasing shares under its authorized program.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on October 31, 2024, to report its financial and operating results for the third quarter ended September 30, 2024. The key information is contained within the press release, furnished as Exhibit 99.1, which details the company's performance during the period. Investors should refer to this press release for specific financial metrics, revenue figures, and operational updates. While the 8-K itself is a procedural filing, the attached press release is the substantive document for understanding Regeneron's third-quarter performance. This filing serves as the official notification of these results to the market, and the press release provides the necessary details to assess the company's progress and financial health as of the end of September 2024.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on October 7, 2024, providing a preliminary update on its expected financial results for the third quarter of 2024. The company anticipates recording an acquired in-process research and development (IPR&D) charge of approximately $56 million on a pre-tax basis. This charge is a result of development milestone and up-front payments tied to collaboration and licensing agreements. This IPR&D charge is projected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.43 for the third quarter. Investors should note that these are preliminary estimates, and the actual results are subject to the company's financial statement closing procedures and could differ. Regeneron emphasizes that acquired IPR&D charges are inherently unpredictable due to the uncertainty in timing and magnitude of such transactions, and therefore are not typically forecasted.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 1, 2024, to report its financial and operating results for the second quarter ended June 30, 2024. The key information is contained within the press release furnished as Exhibit 99.1 to the filing. Investors should review this press release for detailed insights into the company's performance during the quarter, including revenue generation, profit margins, and strategic updates. This filing serves as the official notification of REGN's Q2 2024 performance. While the 8-K itself is brief, the attached press release is the primary source of information for understanding the company's financial health, operational achievements, and outlook. Investors are encouraged to access and analyze Exhibit 99.1 for a comprehensive understanding of the company's recent results and any forward-looking statements.

Regeneron Pharmaceuticals, Inc. reported strong financial results for the second quarter and first half of 2024, demonstrating robust revenue growth and increased profitability. Total revenues increased by 12% year-over-year for the second quarter to $3.55 billion and by 6% for the first half to $6.69 billion, driven by significant contributions from its key products, particularly Dupixent and EYLEA HD. Net product sales saw a healthy increase, with Dupixent sales up 27% in the second quarter and 26% in the first half. EYLEA HD and EYLEA combined U.S. net sales showed a slight increase of 2%, with EYLEA HD sales contributing $304.2 million in the quarter, reflecting strong patient adoption. Collaboration revenue also saw a substantial increase, primarily due to higher profit shares from Dupixent sales. The company's net income grew significantly, reaching $1.43 billion in the second quarter, a 48% increase year-over-year, resulting in diluted EPS of $12.41. For the first half, net income increased by 21% to $2.15 billion, with diluted EPS of $18.68. The company also continued its share repurchase program, repurchasing $601.4 million in the second quarter, underscoring a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. has filed a Current Report on Form 8-K to provide preliminary insights into its second quarter 2024 financial results. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $24 million. This charge, stemming from collaboration and licensing agreements, is expected to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.18 for the quarter. While these figures are preliminary and subject to closing procedures, they offer investors an early look at a specific cost impacting the quarter's profitability.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K report detailing the outcomes of its 2024 Annual Meeting of Shareholders held on June 14, 2024. The primary focus of this filing is the voting results on several key proposals, including the election of directors, ratification of its independent auditor, advisory vote on executive compensation, and a shareholder proposal regarding simple majority voting. All proposals presented to shareholders, with the exception of one, received strong support, indicating continued confidence from the company's investors in its governance and operational direction. Of particular note, all nominated directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm was overwhelmingly ratified. The advisory vote on executive compensation also passed. However, a shareholder proposal advocating for simple majority voting requirements also received a majority of the votes cast, suggesting a desire among some shareholders for changes in the company's voting structure. Investors should monitor any subsequent actions or responses from the company regarding this approved shareholder proposal.

Regeneron Pharmaceuticals, Inc. reported a slight decrease in total revenues to $3,145.0 million for the first quarter of 2024, down from $3,162.1 million in the same period last year. This was primarily driven by a decrease in EYLEA net product sales in the U.S., offset by strong growth in Dupixent, Libtayo, and Praluent. Net income saw a decline to $722.0 million from $817.8 million, resulting in diluted EPS of $6.27 compared to $7.17 year-over-year. Despite the revenue dip, the company demonstrated solid operational cash flow generation. Investment in research and development increased significantly, reflecting continued commitment to pipeline expansion. The company also continues its share repurchase program, with $1.233 billion remaining authorization as of March 31, 2024, and authorized an additional $3.0 billion in April 2024.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 2, 2024, to report its financial and operating results for the first quarter ended March 31, 2024. The press release, filed as Exhibit 99.1, contains the detailed financial data and operational performance for the period. Investors should refer to this press release for comprehensive insights into the company's recent performance. While the 8-K itself is a brief filing, its primary purpose is to officially submit the Q1 2024 earnings press release for public record. This press release will contain key financial metrics such as revenue, earnings per share (EPS), and potentially updates on product sales, pipeline advancements, and strategic outlook. Investors are encouraged to review Exhibit 99.1 for a full understanding of Regeneron's Q1 performance and forward-looking statements.

Regeneron Pharmaceuticals, Inc. (REGN) reported total revenues of $13,117.2 million for the year ended December 31, 2023, an increase of approximately 7.8% compared to the prior year. This growth was primarily driven by strong performance in Dupixent and the launch of EYLEA HD. Net income for the year was $3,953.6 million, resulting in diluted earnings per share of $34.77. The company continues to invest heavily in research and development, with expenses increasing to $4,439.0 million, reflecting progress across its diverse pipeline of product candidates in various therapeutic areas, including ophthalmology, immunology, oncology, and rare diseases. Regeneron maintains a robust financial position, with significant cash and marketable securities, and is actively managing its capital structure through share repurchases.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on February 2, 2024, announcing its financial and operating results for the fourth quarter and full year ended December 31, 2023. The report primarily consists of a press release that details these results, which is furnished as an exhibit. Investors should refer to this press release for a comprehensive overview of the company's performance during the period. While the 8-K itself is brief, the accompanying press release (Exhibit 99.1) contains the critical financial metrics and operational updates that will be of most interest to shareholders. This includes details on revenue, earnings per share, and potentially insights into key drug performance and pipeline developments. Investors are advised to carefully review the furnished press release for specific figures and forward-looking statements.

Regeneron Pharmaceuticals, Inc. (REGN) has announced a planned succession in its finance leadership team. Effective February 5, 2024, following the filing of their 2023 Form 10-K, Christopher Fenimore will be appointed as Senior Vice President, Finance and Chief Financial Officer, succeeding the retiring Robert E. Landry. Concurrently, Jason Pitofsky will be promoted to Vice President, Controller. This transition is part of a previously disclosed CFO succession plan. Mr. Fenimore, with extensive experience within Regeneron and prior roles in the biotech and finance sectors, will see his 2024 base salary adjusted to $660,000 and received a significant equity award in December 2023 valued at $5 million. Mr. Pitofsky's appointment to Controller is a promotion from his previous role as VP, Accounting and Financial Reporting, with no immediate changes to his compensation. Investors can view this as a continuation of internal talent development and a structured handover of critical financial oversight.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on January 8, 2024, providing a corporate update that includes preliminary fourth quarter 2023 financial insights and details on an acquired in-process research and development (IPR&D) charge. The company shared preliminary U.S. net product sales for EYLEA® HD (aflibercept) Injection 8 mg at approximately $123 million and for EYLEA® (aflibercept) Injection at approximately $1.34 billion for the fourth quarter of 2023. These figures indicate continued strong performance from the EYLEA franchise, with EYLEA HD contributing a significant initial amount. Additionally, Regeneron anticipates a $30 million pre-tax acquired IPR&D charge related to an extension of its collaboration with Intellia Therapeutics, Inc. This charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.21 for the fourth quarter. While these are preliminary, unaudited figures, the update provides investors with an early look at key revenue drivers and R&D investment impacting the company's financial performance.

Regeneron Pharmaceuticals, Inc. reported a strong third quarter of 2023, driven by robust growth in key products like Dupixent and Libtayo, alongside collaboration revenues. Total revenues increased to $3.36 billion, a 14.5% rise year-over-year, with net income reaching $1.01 billion. The company also saw significant growth in its marketable securities portfolio and continued to execute its share repurchase program, returning capital to shareholders. Despite a slight decline in Eylea U.S. net product sales due to increased competition, the approval of Eylea HD in August 2023 provides a significant opportunity for future growth in the ophthalmology market. The company's R&D expenses increased, reflecting ongoing investment in its diverse pipeline, including advancements in oncology and immunology. Regeneron maintains a solid financial position with substantial cash and marketable securities, providing flexibility for future investments and strategic initiatives.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 2, 2023, to furnish a press release detailing its financial and operating results for the third quarter ended September 30, 2023. The core of this filing is the announcement of these results, which are crucial for investors to assess the company's performance and future outlook. While the 8-K itself is a brief report, it directs investors to the accompanying press release (Exhibit 99.1) for the detailed financial figures and operational updates. Investors should focus on the data presented in the press release, which typically includes revenue figures, earnings per share, key product sales, and updates on the company's pipeline and strategic initiatives. This information will be vital for understanding the trajectory of Regeneron's key growth drivers and the overall health of its business during the reporting period. The filing serves as the official notification of these results, with the press release providing the comprehensive details.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose an expected $100 million pre-tax acquired in-process research and development (IPR&D) charge for the third quarter of 2023. This charge is primarily related to a development milestone payment for the Phase 1 ALN-APP program in early-onset Alzheimer's disease, stemming from Regeneron's collaboration with Alnylam Pharmaceuticals, Inc. This IPR&D charge is anticipated to reduce both GAAP and non-GAAP net income per diluted share by approximately $0.78 for the quarter. While this charge will impact reported earnings, it represents a milestone achievement in the company's research pipeline. Regeneron notes that these IPR&D charges are inherently unpredictable in timing and magnitude and are therefore not typically forecasted.

This filing is an amendment to a previous 8-K report and serves to clarify Regeneron Pharmaceuticals, Inc.'s decision regarding the frequency of shareholder advisory votes on executive compensation. The company's Board of Directors, accepting the recommendation of its Compensation and Corporate Governance committees, has determined that these advisory votes will continue to be held annually. This decision follows a shareholder vote at the 2023 Annual Meeting of Shareholders held on June 9, 2023, where the option for a one-year frequency received a majority of the votes cast. The amendment, filed on September 7, 2023, with an event date of June 8, 2023, is a procedural update to formally disclose this outcome and the Board's subsequent confirmation.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing significant changes within its board of directors and executive leadership. Notably, the company announced the retirement of its Chief Financial Officer, Robert E. Landry, who has served in that capacity since 2013. Mr. Landry plans to retire in February 2024, and the company has appointed Christopher Fenimore, currently Senior Vice President, Controller, as his successor, ensuring a smooth transition in financial leadership. In addition to the CFO transition, Regeneron has elected two new independent directors to its Board: Dr. Kathryn Guarini and Dr. David P. Schenkein. These appointments are intended to fill existing vacancies and strengthen the Board's expertise. The report also discloses the departure of Dr. Marc Tessier-Lavigne as a director due to potential conflicts arising from increased involvement with other companies. These leadership changes, while significant, are presented as strategic moves to ensure continued strong governance and financial oversight at Regeneron.

Regeneron Pharmaceuticals, Inc. (REGN) reported solid financial results for the second quarter and first half of 2023, demonstrating continued revenue growth driven primarily by Dupixent and Libtayo, which offset a decline in EYLEA sales in the US. Total revenues increased by 10.5% year-over-year for the first six months of 2023. Net income also saw an increase, reaching $1.79 billion for the first half of the year. The company's strong financial position is supported by a robust cash balance and significant investments in research and development, underscoring its commitment to pipeline expansion and innovation. The company is strategically navigating the competitive landscape for EYLEA, facing increased competition and awaiting regulatory decisions on its next-generation aflibercept 8 mg. However, the significant growth in Dupixent and Libtayo, along with progress in its robust pipeline of over 30 product candidates, positions Regeneron for sustained long-term growth. Investors should monitor upcoming regulatory decisions, especially for aflibercept 8 mg, and the continued commercial performance of key growth drivers like Dupixent.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on August 3, 2023, to announce its financial and operating results for the second quarter ended June 30, 2023. The primary purpose of this filing is to furnish the associated press release, which contains the detailed results and operational updates. Investors should refer to the press release (Exhibit 99.1) for the most comprehensive information regarding REGN's performance during the quarter.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 13, 2023, detailing key corporate governance actions and shareholder vote outcomes from its Annual Meeting held on June 9, 2023. The most significant governance change involves an amendment to the company's By-Laws to implement its previously disclosed Board leadership succession plan, allowing for the election of two Co-Chairs of the Board. Shareholders overwhelmingly approved routine matters, including the election of Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2023, and the advisory vote on executive compensation. The company will continue with annual advisory votes on executive compensation. A shareholder proposal related to access to medicine in intellectual property protection was not approved.

Regeneron Pharmaceuticals, Inc. reported its first-quarter 2023 financial results, demonstrating revenue growth and a strong balance sheet. Total revenues increased to $3.16 billion, up from $2.97 billion in the same period last year, driven primarily by a significant increase in collaboration revenue, particularly from the Sanofi antibody collaboration. Net product sales saw a modest increase of $29 million to $1.67 billion, with notable growth in Libtayo and Evkeeza offsetting a decline in EYLEA U.S. sales. The company maintained a solid financial position with approximately $3.9 billion in cash and cash equivalents and over $11 billion in marketable securities. Research and development expenses increased significantly, reflecting continued investment in its robust pipeline, including advancements in immunology, inflammation, and oncology programs. The company also continued its share repurchase program, demonstrating a commitment to returning capital to shareholders.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 4, 2023, to announce its first-quarter 2023 financial and operating results via a press release. While the 8-K itself is brief and primarily serves to incorporate the press release, the key investor information lies within that furnished document. Investors should review the press release for details on revenue, earnings, product performance, and any forward-looking statements or strategic updates from the company during the first quarter of 2023. This filing indicates that the company met its reporting obligations by providing timely financial updates. The press release, incorporated by reference, will contain the specifics regarding the company's performance, including key metrics for its approved products and pipeline developments. Investors interested in Regeneron's performance should look to the details within the press release for a comprehensive understanding of the quarter's outcomes and management's commentary.

Regeneron Pharmaceuticals, Inc. (REGN) announced a significant leadership transition in its upcoming 2023 Annual Meeting of Shareholders. Dr. P. Roy Vagelos, the current Chair of the Board, has decided not to stand for re-election. This marks the end of his tenure, during which he will continue to serve until the conclusion of the meeting on June 9, 2023. The company has stated that Dr. Vagelos's decision was not due to any disagreements regarding the company's operations or policies.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 10, 2023, to disclose an expected acquired in-process research and development (IPR&D) charge for the first quarter of 2023. This charge is primarily related to an upfront payment for their collaboration and license agreement with Sonoma Biotherapeutics, Inc. The company anticipates a pre-tax IPR&D charge of approximately $56 million, which is expected to reduce both GAAP and non-GAAP net income per diluted share by roughly $0.42 for the quarter. While this charge is a notable event impacting short-term profitability per share, investors should note that such IPR&D charges are inherently unpredictable and are not typically forecasted by the company. The disclosed figures are preliminary estimates and are subject to finalization of the company's financial closing procedures. Investors should monitor future filings for finalized financial results and strategic updates regarding the Sonoma Biotherapeutics collaboration.

Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report detailing the execution of Third Amended and Restated Agreements related to a participation agreement, lease, and guaranty. These agreements, effective March 27, 2023, involve Old Saw Mill Holdings LLC as lessee and BA Leasing BSC, LLC as lessor, with Bank of America, N.A. serving as administrative agent. Regeneron Pharmaceuticals, Inc. itself, along with Regeneron Healthcare Solutions, Inc. and Regeneron Genetics Center LLC, are acting as guarantors under these new arrangements.

Regeneron Pharmaceuticals, Inc. (REGN) reported revenues of $12.17 billion for the year ended December 31, 2022, a decrease of approximately 24% compared to $16.07 billion in 2021. This decline was primarily driven by a significant drop in REGEN-COV sales, which were $7.57 billion in 2021 and largely absent in 2022, coupled with a modest increase in EYLEA and Dupixent sales. Net income also decreased substantially from $8.08 billion in 2021 to $4.34 billion in 2022, reflecting the reduced revenues and increased investment in research and development. The company continues to invest heavily in its robust pipeline, with research and development expenses increasing by approximately 25% year-over-year. Key products like EYLEA and Dupixent showed growth, indicating strong performance in core therapeutic areas. Regeneron is also actively managing its capital, evidenced by significant share repurchases and capital expenditures aimed at expanding its manufacturing capacity. The company remains focused on innovation and the development of new therapies across a broad range of serious diseases.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on February 3, 2023, to report its financial and operating results for the fourth quarter and full year ended December 31, 2022. The key details of these results are provided in a press release, which is furnished as an exhibit to this filing. Investors should refer to this press release for specific financial metrics, including revenue, earnings, and updates on key product performance and pipeline developments, which are crucial for understanding the company's current financial health and future outlook.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Current Report (8-K) on January 9, 2023, providing preliminary unaudited financial updates and corporate developments discussed at the J.P. Morgan Healthcare Conference. The company reported strong preliminary U.S. net product sales for EYLEA® (aflibercept) Injection, reaching approximately $6.26 billion for the full year 2022, with $1.50 billion in the fourth quarter. However, fourth-quarter EYLEA sales were impacted by a temporary shift to off-label use of compounded Avastin® and a temporary closure of a patient co-pay assistance fund. Encouragingly, recent data suggests the shift to off-label Avastin is beginning to reverse. Additionally, Regeneron anticipates a $30 million acquired in-process research and development (IPR&D) charge in Q4 2022 and full-year 2022 results, related to an upfront payment for a collaboration with CytomX Therapeutics, Inc. This charge is expected to reduce GAAP and non-GAAP diluted earnings per share by approximately $0.21 for the fourth quarter. Investors should note that these are preliminary, unaudited figures, subject to change upon finalization of financial statements.

Regeneron Pharmaceuticals, Inc. (REGN) has entered into a new $750 million senior unsecured five-year revolving credit facility, replacing its previous facility of the same size. This new credit agreement, effective December 19, 2022, provides Regeneron with financial flexibility for working capital needs and general corporate purposes. The facility features a variable interest rate tied to SOFR or alternate base rate, plus an applicable margin that adjusts based on the company's debt rating and leverage ratio. Notably, the agreement includes an option for Regeneron to incorporate environmental, social, and governance (ESG) targets to potentially adjust pricing, aligning with increasing investor focus on sustainability metrics.

Regeneron Pharmaceuticals, Inc. reported third-quarter and year-to-date results for the period ending September 30, 2022, showing a decrease in total revenues compared to the prior year, largely driven by a significant drop in REGEN-COV sales. Despite this, the company demonstrated robust growth in key products like Dupixent and EYLEA, with Dupixent sales up 40% year-over-year. Operationally, R&D expenses increased, reflecting ongoing investments in the pipeline, and SG&A expenses also rose, partly due to increased commercialization efforts for Libtayo after its global rights acquisition. The company's balance sheet remains strong, with substantial cash and marketable securities. Significant investments were made in acquiring the worldwide rights for Libtayo, impacting cash flows. The company continues its share repurchase program, with approximately $1.186 billion remaining authorized. Investors should note the ongoing litigation concerning Praluent and EYLEA patents, as well as various government investigations. The company's future performance is heavily reliant on the continued success of EYLEA and Dupixent, alongside the progression of its pipeline products.

Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to report its financial and operating results for the third quarter ended September 30, 2022. The key information is detailed in the press release furnished as Exhibit 99.1, which provides the company's performance metrics for the period. Investors should review the press release for specific details on revenue, earnings, and any forward-looking statements or business developments announced. This filing serves as the official notification of the quarterly results and is crucial for understanding the company's recent financial standing and operational achievements.

Regeneron Pharmaceuticals, Inc. (REGN) announced an important change to its Board of Directors through an 8-K filing on October 3, 2022. The company has elected Craig B. Thompson, M.D. as a new director, expanding the Board from 12 to 13 members. Dr. Thompson's appointment is effective immediately and he will serve until the 2023 Annual Shareholder Meeting. This addition signifies a potential strengthening of the Board's expertise, particularly in technology, as Dr. Thompson has also been appointed to the Board's Technology Committee. Investors should note that Dr. Thompson's compensation will align with the company's existing non-employee director compensation structure, as previously detailed in their proxy statement. There are no disclosed understandings or arrangements with other parties regarding his selection. This move is a governance update that could impact strategic oversight and technological direction for Regeneron.

Regeneron Pharmaceuticals, Inc. reported its financial results for the second quarter and first half of 2022. The company saw a significant decrease in total revenues for both the three and six-month periods compared to the prior year, primarily driven by the absence of REGEN-COV sales, which were substantial in the first half of 2021. Despite the revenue decline, Regeneron demonstrated strong operational cash flow generation. Key product sales, particularly for EYLEA and Dupixent, showed robust year-over-year growth, indicating continued strong demand for these core products. The company also made significant strategic moves, including the acquisition of Checkmate Pharmaceuticals, which added an oncology pipeline asset, and an amendment to its Immuno-oncology collaboration with Sanofi, granting Regeneron exclusive worldwide rights to Libtayo. These strategic actions, coupled with a strong cash position and an ongoing share repurchase program, position Regeneron for future growth despite near-term revenue headwinds from the REGEN-COV wind-down.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on August 3, 2022, primarily to report its financial and operating results for the second quarter ended June 30, 2022. The key information is contained within the press release furnished as Exhibit 99.1. Investors should review this press release for details on the company's performance, including revenue, earnings, and any significant operational updates or strategic developments during the quarter. This filing serves as the official channel for disseminating the company's quarterly financial performance. While the 8-K itself is brief, the attached press release contains the critical data points that stakeholders will use to assess Regeneron's current financial health and its trajectory. It's important to note that the information furnished under Item 2.02 is not considered 'filed' for certain regulatory purposes, but it is the primary source of the disclosed financial results.

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 15, 2022, detailing the outcomes of its 2022 Annual Meeting of Shareholders held on June 10, 2022. The primary focus of this report is the voting results on key corporate governance and financial matters. Investors will be interested to note that all proposed items were overwhelmingly approved by shareholders, indicating strong support for the company's management and strategic direction. Specifically, the election of Class I directors received substantial support, with all nominees elected to serve until the 2025 Annual Meeting. Furthermore, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year 2022, a crucial vote of confidence in the company's financial oversight. Finally, an advisory vote on executive compensation was also approved, suggesting shareholder satisfaction with the remuneration of the company's named executive officers.